Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
100% citation coverage2 regulatory sources
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
Intelligence Snapshot
Executive Summary
The FDA approved Eisai's BLA for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025, with U.S. availability reported in October 2025.
Key Insights
- The maintenance dose is 360 mg administered weekly via subcutaneous injection.
-
LEQEMBI is an amyloid beta-directed antibody indicated for treatment of Alzheimer's…
LEQEMBI is an amyloid beta-directed antibody indicated for treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia .
-
The LEQEMBI IQLIK formulation is positioned to reduce healthcare resources associated…
The LEQEMBI IQLIK formulation is positioned to reduce healthcare resources associated with IV maintenance dosing, such as preparation for infusion.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Loading intelligence…
Loading intelligence…
Quick Answer
The FDA approved Eisai's BLA for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025, with U.S. availability reported in October 2025.
Key Questions
- Does Biogen make LEQEMBI?
- What is LEQEMBI subcutaneous approval?
- Who is LEQEMBI intended for?
- What should teams watch next?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Leqembi.
Unlock full calendar →Biogen pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents15 sections
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The companies reported U.S. availability in October 2025.
IntelligenceRegulatory Impact
FDA and EMA decisions frame this story. Regulatory relevance is high for Alzheimer's disease, with Leqembi and lecanemab-irmb most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
Key Takeaways
- The FDA approved Eisai's BLA for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025, with U.S. availability reported in October 2025.
- The maintenance dose is 360 mg administered weekly via subcutaneous injection.
- LEQEMBI is an amyloid beta-directed antibody indicated for treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia.
- The LEQEMBI IQLIK formulation is positioned to reduce healthcare resources associated with IV maintenance dosing, such as preparation for infusion.
IntelligenceCompetitive Intelligence
Biogen and Eisai are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
What changed with LEQEMBI subcutaneous approval?
The FDA approved Eisai's Biologics License Application for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In October 2025, Eisai and Biogen reported that lecanemab-irmb is now available in the United States as a subcutaneous maintenance treatment.
The regulatory approval centers on a specific maintenance regimen: Eisai has developed a subcutaneous maintenance therapy dose of 360 mg weekly. This formulation, branded as LEQEMBI IQLIK, represents an alternative delivery method to intravenous infusion maintenance.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for Alzheimer's disease. Expect implications for pricing, access, and launch sequencing.
The label remains focused on early Alzheimer's disease
LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease. The approved indication is narrowly defined: treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
The subcutaneous maintenance formulation does not expand the eligible population; it only changes the route of administration for patients already within the approved indication.
IntelligenceStrategic Takeaways
The FDA approved Eisai's BLA for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025, with U.S. availability reported in October 2025. The maintenance dose is 360 mg administered weekly via subcutaneous injection. LEQEMBI is an amyloid beta-directed antibody indicated for treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia .
How does subcutaneous maintenance dosing change administration?
The LEQEMBI IQLIK formulation has the potential to reduce healthcare resources associated with IV maintenance dosing, such as preparation for infusion. Weekly subcutaneous injections represent an alternative to intravenous infusion protocols.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources.
What to watch: LEQEMBI IQLIK commercialization milestones
For investors and BD professionals, the subcutaneous maintenance approval is a formulation and delivery milestone. The drug's mechanism and indication remain unchanged; only the administration route has evolved.
Several clinical trials are actively investigating LEQEMBI in early Alzheimer's disease and related conditions. A postmarketing study of LEQEMBI in South Korean participants with Alzheimer's disease is recruiting, as is the Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry. Additionally, a Phase 2 study of E2814 with concurrent lecanemab treatment in early Alzheimer's disease is active but not recruiting, and a Phase 4 real-world safety and efficacy study of lecanemab in early Alzheimer's disease is underway.
Regulatory and clinical context
LEQEMBI's FDA label specifies amyloid beta-directed antibody pharmacology and Eisai Inc. as the manufacturer.
Drug Snapshot
| Drug | lecanemab-irmb |
|---|---|
| Generic name | LECANEMAB |
| Drug class | Amyloid Beta-directed Antibody [EPC] |
| Manufacturer | Eisai Inc. |
| Route | INTRAVENOUS |
| Indication | 1 INDICATIONS AND USAGE LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 ) |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 )
- lecanemab-irmb is_class Amyloid Beta-directed Antibody [EPC]
- Eisai Inc. develops lecanemab-irmb
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT06810960 | A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease | RECRUITING | — | Eisai Korea Inc. |
| NCT05999084 | Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry | RECRUITING | — | Emory University |
| NCT06602258 | A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | PHASE2 | Eisai Inc. |
| NCT05469009 | Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy | ACTIVE_NOT_RECRUITING | EARLY_PHASE1 | Ali Rezai |
| NCT07034222 | 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING | PHASE4 | Ruijin Hospital |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Institute of Mental Health (NIMH) | Alzheimer's disease | 1 |
| Xuanwu Hospital, Beijing | Alzheimer's disease | 1 |
| National Institute on Aging (NIA) | Alzheimer's disease | 1 |
| Columbia University | Alzheimer's disease | 1 |
| Janssen Pharmaceutica N.V., Belgium | Alzheimer's disease | 1 |
Timeline
- Recruiting trial NCT06810960 (phase n/a)
- Recruiting trial NCT05999084 (phase n/a)
- Active_Not_Recruiting trial NCT06602258 (PHASE2)
- Active_Not_Recruiting trial NCT05469009 (EARLY_PHASE1)
- Active_Not_Recruiting trial NCT07034222 (PHASE4)
Frequently Asked Questions
Does Biogen make LEQEMBI?
LEQEMBI (lecanemab-irmb) is manufactured by Eisai Inc. Eisai and Biogen jointly announced the U.S. availability of the subcutaneous maintenance formulation in October 2025.
What is LEQEMBI subcutaneous approval?
The FDA approved subcutaneous maintenance dosing in August 2025, with the 360 mg weekly subcutaneous formulation becoming available in the U.S. in October 2025.
Who is LEQEMBI intended for?
LEQEMBI is indicated for treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease. The subcutaneous formulation does not expand this indication.
What should teams watch next?
Monitor completion timelines for ongoing postmarketing trials including the South Korean and Georgia registry studies.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About Alzheimer's disease
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow Leqembi developments
FDA alzheimer's disease alerts and Leqembi pipeline updates, every Monday.
- Sources analyzed
- 2
- Evidence strength
- 93/100
- Last verified
- Jun 7, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
